Navigation Links
Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have,Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - Panacos Pharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the results of a new study indicating that HIV resistant to Protease Inhibitors (PI) may have reduced potential for the development of resistance to the HIV maturation inhibitor bevirimat in laboratory assays. The study, carried out by scientists in Dr. Eric Freed's group at the HIV Drug Resistance Program at the National Cancer Institute, Frederick, MD, in collaboration with Panacos, was presented at the Cold Spring Harbor Laboratory's (CSHL) Retrovirus Conference held May 22-27, 2007 in Cold Spring Harbor, NY.

While resistance to bevirimat has not yet been reported in clinical studies, bevirimat-resistant HIV can be generated in the laboratory, as is the case with other HIV drugs. In previous studies where HIV was grown for several weeks in cell culture in the presence of bevirimat at suboptimal concentrations, mutations conferring resistance to bevirimat were found exclusively at or near bevirimat's target, the capsid-SP1 cleavage site in the HIV Gag protein. Cleavage of capsid from SP1, the final step in viral maturation, is mediated by the viral protease enzyme. Bevirimat inhibits this cleavage step by interacting with the capsid-SP1 junction in Gag, suggesting that pre-existing PI resistance mutations may have an impact on the development of bevirimat resistance.

In the new study, wild-type HIV, as well as HIV bearing major mutations conferring PI resistance, were grown in cell culture in the presence of bevirimat at suboptimal concentrations. Bevirimat resistance developed after several weeks in both wild-type and PI-resistant HIV, but took more than twice as long to develop in the PI-resistant virus. The bevirimat resistance mutation that appeared in PI-resistant virus was located at th
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... Education Conference (I/ITSEC) has sold all its ... Center in Orlando. Occupying almost 200,000 square feet, ... simulation technology ever. The I/ITSEC Conference is ... the Orange County Convention Center in Orlando, Florida. ...
... the first robotic assisted surgery to gynaecologic cancer patient in August 2008. ... ... undergo surgery for gynaecological cancers now have an option to have surgery ... back on their feet faster while being just as effective in removing ...
... Smoked During Pregnancy More Than Twice as Likely to ... OAKLAND, Calif., Nov. 5 Babies whose mothers,smoked during ... a cleft,palate or lip as those whose mothers didn,t, ... confirms earlier findings, it is unique because it,did not ...
... Foundation Health Plan,Inc., Kaiser Foundation Hospitals and their ... for the quarter ended September,30, 2008, compared to ... KFHP/H,s operating income in the third quarter ... same quarter last year. Financial market,volatility impacted KFHP/H,s ...
... Increases 18.9% ... Recurring Diluted FAD Per Share Increases ... Third Quarter Investments Total $125 Million, NEWPORT BEACH, Calif., Nov. 4 ... investment activity for the third quarter and the nine months ended,September 30, 2008., ...
... ad has been produced by,an organization not affiliated with ... organization behind the ad., As we have stated ... other religion. But it is wrong for the Mormons ... California through the ballot box, We note Mr. ...
Cached Medicine News:Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 2Health News:World's Largest Modeling and Simulation Exhibition Sells Out for '08 3Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 2Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 3Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 4Health News:Singapore Medicine - First in South East Asia to Offer Robotic Surgery for Gynaecologic Cancers 5Health News:Moms' Smoking Linked to Increased Risk of Birth Defects 2Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 4Health News:NHP Reports Third Quarter 2008 Earnings 2Health News:NHP Reports Third Quarter 2008 Earnings 3Health News:NHP Reports Third Quarter 2008 Earnings 4Health News:NHP Reports Third Quarter 2008 Earnings 5Health News:NHP Reports Third Quarter 2008 Earnings 6Health News:NHP Reports Third Quarter 2008 Earnings 7Health News:NHP Reports Third Quarter 2008 Earnings 8Health News:NHP Reports Third Quarter 2008 Earnings 9Health News:NHP Reports Third Quarter 2008 Earnings 10Health News:NHP Reports Third Quarter 2008 Earnings 11Health News:NHP Reports Third Quarter 2008 Earnings 12Health News:NHP Reports Third Quarter 2008 Earnings 13Health News:NHP Reports Third Quarter 2008 Earnings 14Health News:NHP Reports Third Quarter 2008 Earnings 15Health News:NHP Reports Third Quarter 2008 Earnings 16
... the cornea for centration of the flap and ... and enhancement cases. The corneal marker has a ... alignment of the flap after treatment. The spatula ... and to flood it back into place following ...
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Short handled spatula for use through the side port stab incision. The malleable silver 0.5 mm tip can be shaped to the surgeon's preference for maximum control. Round serrated handle....
... to enter a side-port stab incision ... manipulate the lens nucleus in the ... rotating and cracking the nucleus. It ... and curved shaft which facilitates nuclear ...
Medicine Products: